Behavioral Activation and Risk Reduction for Stimulant Use Among Sexually Active Adolescents and Young Adults
IMPACT
Hybrid Type 2 Effectiveness-Implementation Trial of Status Neutral, Integrated Behavioral Activation and Risk Reduction Intervention for Stimulant Use Among Sexually Active Adolescents and Young Adults (Project IMPACT)
3 other identifiers
interventional
360
1 country
2
Brief Summary
The use of behavioral intervention to reduce stimulant use and concurrent HIV sexual transmission risk.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable hiv
Started Nov 2025
Typical duration for not_applicable hiv
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 30, 2024
CompletedFirst Posted
Study publicly available on registry
June 5, 2024
CompletedStudy Start
First participant enrolled
November 4, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 31, 2028
January 12, 2026
January 1, 2026
2.7 years
May 30, 2024
January 8, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Distinct acts of condomless sex without the protection of PrEP or viral suppression.
The number of times participants report engaging in condomless sex without the protection of PrEP (for those not living with HIV) or viral suppression (for those living with HIV).
Participants will recall and report acts of condomless sex and medication adherence for the 30 days prior to each of 4 visits: Baseline, Month 4, Month 8 and Month 12.
Secondary Outcomes (1)
Days of stimulant use
Participants will recall and report the number of days they used stimulants out of the 30 days prior to each of 4 visits and will also have urine drug testing done. The visits are at: Baseline, Month 4, Month 8 and Month 12.
Study Arms (2)
IMPACT Group
EXPERIMENTALParticipants who report stimulant use in the context of condomless sex will be randomized using a 2:1 allocation ratio with two-thirds being allocated to the IMPACT intervention.
Enhanced Standard of Care (eSOC) Group
ACTIVE COMPARATORParticipants who report stimulant use in the context of condomless sex will be randomized using a 2:1 allocation ratio with one-third being allocated to the eSOC intervention.
Interventions
The IMPACT intervention includes 10 sessions: 2 sessions of HIV sexual risk reduction (RR) counseling, 1 session focused on orienting and rationale of behavioral activation (BA), 6 sessions integrating BA and sexual RR counseling (including PrEP or ART and HIV care), and 1 final session on strategies for slip-ups and recurrence management.
The eSOC group includes 2 sessions of HIV sexual RR counseling.
Eligibility Criteria
You may qualify if:
- Age 16-24 years, inclusive, at enrollment
- Male or female
- Self-reports condomless anal or vaginal sex while using stimulants (5 hour prior to, or during sex) within the last 4 months; stimulants is defined as crystal methamphetamine, cocaine, and MDMA (e.g., ecstasy, molly)
- Willing and able to provide written informed consent for study participation
- Access to a computer/smartphone/tablet that can use video chat (e.g., Zoom or Google Meet)
- Provide a mailing address where they can receive a package
- Access to stable internet that they can use for more than 2 hours at a time
- Have a private place (where no one else can see or hear) where they can complete visits online
- Reside within the continental U.S.
You may not qualify if:
- Unable to provide informed consent due to severe mental or physical illness
- Concurrent enrollment in another HIV prevention or treatment study (enrollment in a substance treatment program is acceptable)
- Randomized to IMPACT arm prior to March 2025 study stop
- Non-English-speaking
- Is currently incarcerated or pending incarceration
- Is currently pregnant or planning to become pregnant
- Any other medical condition, medical/behavioral intervention, or other condition that, in the opinion of the Project Lead or designee, could interfere with the safety of participants or staff, adherence to study procedures, or compromise interpretation of study results
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
University of California, Los Angeles
Los Angeles, California, 90095, United States
Brown University
Providence, Rhode Island, 02912, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Katie Biello, PhD, MPH
Brown University
- STUDY CHAIR
Matthew Mimiaga, ScD, MPH
University of California, Los Angeles
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 30, 2024
First Posted
June 5, 2024
Study Start
November 4, 2025
Primary Completion (Estimated)
July 31, 2028
Study Completion (Estimated)
July 31, 2028
Last Updated
January 12, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share